Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: the COREYA Propensity-score Adjusted Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 16

PMID 23152890

Citations 3

Authors

Laurent Hocqueloux

Philippe Choisy

Gwenael Le Moal

Francoise Borsa-Lebas

David Plainchamp

Eric Legac

Thierry Prazuck

Xavier De La Tribonniere

Yazdan Yazdanpanah

Jean-Jacques Parienti

Affiliations

Soon will be listed here.

Abstract

Background: Among HIV-1 infected patients who achieved virologic suppression, the use of atazanavir without pharmacologic boosting is debated. We evaluated the efficacy and tolerance of maintenance therapy with unboosted atazanavir in clinical practice.

Methods And Results: This multicenter retrospective cohort study evaluated the efficacy of switching HIV-1-infected patients controlled on triple therapy to unboosted (ATV(0), n = 98) versus ritonavir-boosted atazanavir (ATV/r, n = 254) +2 nucleos(t)ide reverse transcriptase inhibitors. The primary endpoint was time to virologic failure (VF, >200 copies/mL). ATV groups were compared controlling for potential confounding bias by inverse probability weighted Cox analysis and propensity-score matching. Overall and adjusted VF rates were similar for both strategies. Both strategies improved dyslipidemia and creatininemia, with less jaundice in the ATV(0) group.

Conclusion: In previously well-suppressed patients, within an observational cohort setting, ATV(0)-based triple-therapy appeared as effective as ATV/r- based triple-therapy to maintain virologic suppression, even if co-administered with TDF, but was better tolerated.

Citing Articles

Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France.

Demessine L, Peyro-Saint-Paul L, Gardner E, Ghosn J, Parienti J Open Forum Infect Dis. 2019; 6(3):ofz051.

PMID: 30949521 PMC: 6440683. DOI: 10.1093/ofid/ofz051.

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

Wohl D, Bhatti L, Small C, Edelstein H, Zhao H, Margolis D HIV Med. 2015; 17(2):106-17.

PMID: 26176344 PMC: 5034844. DOI: 10.1111/hiv.12281.

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

Wohl D, Bhatti L, Small C, Edelstein H, Zhao H, Margolis D PLoS One. 2014; 9(5):e96187.

PMID: 24825167 PMC: 4019479. DOI: 10.1371/journal.pone.0096187.

References

Obel N, Farkas D, Kronborg G, Larsen C, Pedersen G, Riis A . Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2009; 11(2):130-6. DOI: 10.1111/j.1468-1293.2009.00751.x. View

Valantin M, Bittar R, de Truchis P, Bollens D, Slama L, Giral P . Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010; 65(3):556-61. DOI: 10.1093/jac/dkp462. View

Aldous J, Haubrich R . Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2010; 4(6):459-66. PMC: 2946177. DOI: 10.1097/COH.0b013e328331dea5. View

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A . Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010; 170(14):1228-38. DOI: 10.1001/archinternmed.2010.197. View

Ickovics J, Cameron A, Zackin R, Bassett R, Chesney M, Johnson V . Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002; 7(3):185-93. DOI: 10.1177/135965350200700308. View

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A . Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010; 24(8):1228-30. DOI: 10.1097/QAD.0b013e328339192f. View

Giuntini R, Martinelli C, Ricci E, Vichi F, Gianelli E, Madeddu G . Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med. 2009; 11(1):40-5. DOI: 10.1111/j.1468-1293.2009.00740.x. View

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C . Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007; 44(11):1484-92. DOI: 10.1086/517497. View

Taburet A, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V . Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004; 48(6):2091-6. PMC: 415627. DOI: 10.1128/AAC.48.6.2091-2096.2004. View

10.

Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte A, De Wit S . Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010; 17(5):491-501. DOI: 10.1097/HJR.0b013e328336a150. View

11.

DAgostino Jr R . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265-81. DOI: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b. View

12.

Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N . Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother. 2011; 66(10):2372-8. DOI: 10.1093/jac/dkr316. View

13.

Austin P, Grootendorst P, Anderson G . A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2006; 26(4):734-53. DOI: 10.1002/sim.2580. View

14.

Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M . No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012; 61(4):441-7. DOI: 10.1097/QAI.0b013e31826f993c. View

15.

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G . Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010; 15(7):993-1002. DOI: 10.3851/IMP1666. View

16.

Sabin C, Worm S, Weber R, Reiss P, El-Sadr W, Dabis F . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371(9622):1417-26. PMC: 2688660. DOI: 10.1016/S0140-6736(08)60423-7. View

17.

Parienti J, Ragland K, Lucht F, de La Blanchardiere A, Dargere S, Yazdanpanah Y . Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010; 50(8):1192-7. PMC: 3591724. DOI: 10.1086/651419. View

18.

Squires K, Young B, DeJesus E, Bellos N, Murphy D, Zhao H . Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010; 24(13):2019-27. DOI: 10.1097/QAD.0b013e32833bee1b. View

19.

Calcagno A, Bonora S, Tettoni M, DAvolio A, Di Perri G, Lanzafame M . Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. J Acquir Immune Defic Syndr. 2009; 52(3):431-2. DOI: 10.1097/QAI.0b013e3181b08f09. View

20.

Robins J, Hernan M, Brumback B . Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11(5):550-60. DOI: 10.1097/00001648-200009000-00011. View